An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation
Authors:
Open Access
- 25 April 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 99 (3) , 466-473
Abstract
Our study was performed to evaluate the diagnostic usefulness of %fPSA alone and combined with an ANN at different PSA concentration ranges, including the low range 2–4 ng/ml, to improve the risk assessment of prostate cancer. A total of 928 men with prostate cancer and BPH without any pretreatment of the prostate in the PSA range 2–20 ng/ml were enrolled in the study between 1996 and 2001. An ANN with input data of PSA, %fPSA, patient's age, prostate volume and DRE status was developed to calculate the individual's risk before performing a prostate biopsy within the different PSA ranges 2–4, 4.1–10 and 10.1–20 ng/ml. ROC analysis and cut‐off calculations were used to estimate the diagnostic improvement of %fPSA and ANN in comparison to PSA. At the 90% sensitivity level, %fPSA and ANN performed better than PSA in all ranges, enhancing the specificity by 15–28% and 32–44%, respectively. For the low PSA range 2–4 ng/mL, we recommend a first‐time biopsy at an ANN specificity level of 90%. For PSA 4–10 ng/mL, we recommend a first‐time biopsy based on the ANN at the 90% sensitivity level. Use of an ANN enhances the %fPSA performance to further reduce the number of unnecessary biopsies within the PSA range 2–10 ng/ml.Keywords
This publication has 44 references indexed in Scilit:
- Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 ?g/L: Are they useful tools for early detection and screening of prostate cancer?International Journal of Cancer, 2001
- A VALIDATED STRATEGY FOR SIDE SPECIFIC PREDICTION OF ORGAN CONFINED PROSTATE CANCER: A TOOL TO SELECT FOR NERVE SPARING RADICAL PROSTATECTOMYJournal of Urology, 2001
- PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIALJournal of Urology, 1999
- THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 1998
- A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serumUrology, 1997
- Prostate Cancer Detection in Men With Serum PSA Concentrations of 2.6 to 4.0 ng/mL and Benign Prostate ExaminationJAMA, 1997
- Re: Editorial: Can Prostate Specific Antigen Derivatives Reduce the Frequency of Unnecessary Prostate Biopsies?Journal of Urology, 1997
- The Free-to-Total Serum Prostate Specific Antigen Ratio for Staging Prostate CarcinomaJournal of Urology, 1997
- Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total psa, prostate volume, and ageUrology, 1996
- Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for WindowsScandinavian Journal of Clinical and Laboratory Investigation, 1995